1-13 of 13
Fei Fei Liu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-term Follow-up from Qualitative Interviews of Patients with Relapsed or Refractory Large B-Cell Lymphoma on Their Treatment Experience While Enrolled in a Lisocabtagene Maraleucel Study

Pere Barba, Sally Lanar, Fei Fei Liu, Laurie Eliason, Kshawna Askew, Jennifer Devlen, Ulrika Furustrand, Ana Kostic
Journal: Blood
Blood (2023) 142 (Supplement 1): 7352.
https://doi.org/10.1182/blood-2023-178858
Published: 2023
Journal Articles

Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)

Jennifer L. Crombie, Loretta J. Nastoupil, Charalambos Andreadis, Iris Isufi, Bradley Hunter, Allison Winter, Brian Hess, Stefan K. Barta, Michael J. Frigault, Maria Lia Palomba, Natalie S. Grover, Michael D. Jain, Tamara K. Moyo, Sagar S. Patel, Priyanka A Pophali, David Bernasconi, Charimar Santiago Parrilla, Amani Kitali, Fei Fei Liu, Mecide Gharibo, Marcelo Pasquini
Journal: Blood
Blood (2023) 142 (Supplement 1): 104.
https://doi.org/10.1182/blood-2023-180242
Published: 2023
Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)

Jeremy S. Abramson, Manali Kamdar, Fei Fei Liu, Alessandro Crotta, Alessandro Previtali, Sven L. Klijn, Pearl Wang, Aaron Situ, Yixie Zhang, Ashley Bonner, Matthew A. Lunning
Journal: Blood
Blood (2022) 140 (Supplement 1): 4655–4656.
https://doi.org/10.1182/blood-2022-160216
Published: 2022
Journal Articles

Comparative Effectiveness of Lisocabtagene Maraleucel (Liso-cel) in PILOT in Patients (Pt) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) for Whom Transplant Was Not Intended (TNI) Versus Conventional Second-Line (2L) Chemotherapy Regimens in the Real World

Nilanjan Ghosh, Alison R. Sehgal, Fei Fei Liu, Ana Kostic, Alessandro Crotta, Lily Peng, Marc De Benedetti, Leo I. Gordon
Journal: Blood
Blood (2022) 140 (Supplement 1): 10430–10431.
https://doi.org/10.1182/blood-2022-159686
Published: 2022
Journal Articles

Real-World Treatment Patterns and Costs of Chimeric Antigen Receptor (CAR) T Cell Therapies, Polatuzumab Vedotin-Piiq (Pola), and Tafasitamab-Cxix (Tafa) in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Fei Fei Liu, Krishnaveni Subbiah, Tao Gu, Trong Kim Le
Journal: Blood
Blood (2022) 140 (Supplement 1): 2414–2415.
https://doi.org/10.1182/blood-2022-162587
Published: 2022
Journal Articles

Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community/Nonuniversity Setting: Patient-Reported Outcomes/Health-Related Quality of Life from the Outreach Study

Yuliya Linhares, Fei Fei Liu, Cesar Freytes, Mohamad Cherry, Ling Shi, Weiqin Liao, Julia Braverman, Ricardo Espinola, Min Vedal, Bassam Mattar
Journal: Blood
Blood (2022) 140 (Supplement 1): 10930–10931.
https://doi.org/10.1182/blood-2022-159645
Published: 2022
Journal Articles

Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma ( LBCL): Results from the Phase 3 Transform Study

Jeremy S. Abramson, Scott R. Solomon, Jon E. Arnason, Patrick B. Johnston, Bertram Glass, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Fei Fei Liu, Julia Braverman, Shien Guo, Ling Shi, Manali Kamdar
Journal: Blood
Blood (2021) 138 (Supplement 1): 3845.
https://doi.org/10.1182/blood-2021-151611
Published: 2021
Journal Articles

Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion

Tanya Siddiqi, Ulrich Jaeger, Olga Moshkovich, Julia Braverman, Fei Fei Liu, Sally Lanar, Matthew Miera, Selam Shah, Jennifer Devlen, Gilles Salles
Journal: Blood
Blood (2021) 138 (Supplement 1): 4098.
https://doi.org/10.1182/blood-2021-151823
Published: 2021
Journal Articles

Cost-Effectiveness of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Treatment of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Christopher Parker, Fei Fei Liu, Kristen Deger, Conrado Franco-Villalobos, Irina Proskorovsky, Scott J Keating, Sonja Sorensen, Emily Dorman
Journal: Blood
Blood (2021) 138 (Supplement 1): 3003.
https://doi.org/10.1182/blood-2021-150755
Published: 2021
Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

David G. Maloney, MD PhD, John Kuruvilla, MD, Christopher P Fox, MD PhD, Guillaume Cartron, MD PhD, Daniel Li, PhD, Jens Hasskarl, MD, Ashley Bonner, PhD, Yixie Zhang, PhD, Fei Fei Liu, BSc, MBA
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-137719
Published: 2020
Journal Articles

Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy

Tanya Siddiqi, MD, Ulrich Jaeger, MD, Olga Moshkovich, MPH, Jennifer Devlen, PhD, Matthew Miera, BSc, Agnes Williams, MSc, Jens Hasskarl, MD, Fei Fei Liu, BSc, MBA, Julia Braverman, PhD, Gilles Salles, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-137656
Published: 2020
Journal Articles

Persistent Red Blood Cell (RBC) Transfusion Is Associated with Increased Mortality Risk in Transfusion-Dependent (TD) Patients with Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS+)

Rena Buckstein, MD FRCPC, Nancy Zhu, MD, Mary-Margaret Keating, MD, Brian Leber, MD, Lisa Chodirker, MD, Mitchell Sabloff, Grace Cristou, Heather A. Leitch, MD, Eve St. Hilaire, Nicholas Finn, MD, Karen W.L. Yee, MD, Mohamed Elemary, MD, Versha Banerji, MD, Martha Lenis, Aksharh Kirubananthaan, Fei Fei Liu, Derek Tang, PhD BSPharm, Chris Westcott, Vicky Wei-Hsuen Huang, Di Wang, Chris Cameron, Jessica Morison, Paul Spin, Alexandre Mamedov
Journal: Blood
Blood (2019) 134 (Supplement_1): 3012.
https://doi.org/10.1182/blood-2019-123684
Published: 2019
Journal Articles

Systematic Literature Review of the Clinical Evidence in Relapsed/Refractory (R/R) Large B-Cell Lymphoma

David G. Maloney, MD PhD, Fei Fei Liu, Lisette Nientker, Cathelijne Alleman, Brian Hutton, PhD, Jacob Garcia, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5821.
https://doi.org/10.1182/blood-2019-127664
Published: 2019